博济医药(300404) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue reached ¥222,869,199.85, an increase of 3.78% year-over-year, while year-to-date revenue was ¥584,317,656.85, up 5.06% compared to the previous year[5] - Net profit attributable to shareholders was ¥6,344,040.03, down 51.73% year-over-year, and year-to-date net profit was ¥21,913,904.30, a decrease of 49.36%[5] - Basic earnings per share for the quarter was ¥0.0165, a decline of 52.03%, while year-to-date basic earnings per share was ¥0.0571, down 49.60%[5] - Total comprehensive income for the year-to-date was ¥23,471,634.26, down 47.83% from the previous year[11] - The net profit for the current period is CNY 23,867,516.19, a decrease of 47.4% compared to CNY 45,361,752.11 in the previous period[26] - The total profit for the current period is CNY 18,330,632.81, down from CNY 31,163,247.92, reflecting a decline of 41.3%[26] - Operating profit for the current period is CNY 18,609,104.55, compared to CNY 31,224,117.99 in the previous period, indicating a decrease of 40.8%[26] - The total comprehensive income for the current period is CNY 23,471,634.26, a decrease of 47.8% from CNY 44,992,255.06 in the previous period[26] Assets and Liabilities - Total assets increased to ¥1,587,919,783.62, reflecting a growth of 9.47% from the end of the previous year[5] - Total liabilities increased to ¥533,808,008.31 from ¥448,838,881.46, reflecting a growth of 19.0%[24] - The company's equity attributable to shareholders rose to ¥1,020,241,096.25 from ¥973,381,474.22, an increase of 4.8%[24] - Non-current assets totaled ¥663,301,584.37, slightly down from ¥670,313,529.45, a decrease of 1.5%[23] Cash Flow - Cash flow from operating activities for the year-to-date was ¥7,794,974.90, a significant increase of 148.60% compared to the same period last year[13] - Cash flow from operating activities shows a net inflow of CNY 7,794,974.90, a significant improvement from a net outflow of CNY 16,040,097.77 in the previous period[27] - Cash flow from investing activities resulted in a net outflow of CNY 151,446,023.16, slightly improved from CNY 186,702,227.12 in the previous period[28] - Cash flow from financing activities generated a net inflow of CNY 18,593,184.08, compared to a net outflow of CNY 62,737,410.37 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,555[14] - The largest shareholder, Wang Tingchun, holds 30.77% of the shares, amounting to 118,674,370 shares, with 26,603,600 shares pledged[14] - The number of shares with limited sales conditions held by Wang Tingchun is 89,005,777, which are locked for 36 months[16] - As of September 30, 2025, the company's total share capital has increased from 381,989,708 shares to 385,556,078 shares[18] Operational Highlights - The company has signed new business contracts worth approximately 1.248 billion RMB, representing a year-on-year growth of about 9.85%[17] - The company received three invention patents during the reporting period, including methods for the preparation of specific drugs[19] - The company obtained clinical trial approval for its drug "FCZR" from the National Medical Products Administration[18] - The company's governance structure has been optimized following the completion of the capital change registration[18] Costs and Expenses - Total operating costs amounted to ¥554,800,483.18, up from ¥519,937,507.73, reflecting a rise of 6.7%[25] - Research and development expenses decreased to ¥38,925,834.02 from ¥44,450,607.56, a decline of 12.4%[25] - The company's cash and cash equivalents decreased to ¥143,763,081.57 from ¥270,133,867.18, a decline of 46.8%[21] - Accounts receivable increased to ¥195,581,145.66 from ¥169,703,594.65, representing a growth of 15.2%[21] - Inventory rose to ¥242,017,600.69 from ¥189,485,440.64, marking an increase of 27.7%[21] Investment Income - The company experienced a 71.48% decrease in investment income, amounting to ¥422,611.89, mainly due to reduced financial product returns[11] - The company reported a 602.31% increase in trading financial assets, totaling ¥166,292,060.25, primarily due to the purchase of financial products[9] - Contract assets rose by 58.46% to ¥126,170,228.44, attributed to increased revenue during the period[9]